INT954

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1979
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 7.60
Pain Relevance 1.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (GHRH) extracellular region (GHRH) cell-cell signaling (GHRH)
Anatomy Link Frequency
pituitary 6
body 4
Blood 2
fat 2
gonadal 2
GHRH (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 4 100.00 Very High Very High Very High
Pain 11 98.64 Very High Very High Very High
narcan 4 97.98 Very High Very High Very High
withdrawal 4 96.96 Very High Very High Very High
opiate 2 93.52 High High
antagonist 81 93.00 High High
imagery 1 91.52 High High
Somatostatin 33 84.80 Quite High
pain labor 1 75.00 Quite High
qutenza 1 69.48 Quite High
Disease Link Frequency Relevance Heat
Acromegaly 10 100.00 Very High Very High Very High
Cancer 91 99.98 Very High Very High Very High
Hypoglycemia 22 99.76 Very High Very High Very High
Growth Problems 140 99.62 Very High Very High Very High
Adenoma 14 99.36 Very High Very High Very High
Pain 9 98.64 Very High Very High Very High
Premature Birth 141 96.84 Very High Very High Very High
Targeted Disruption 68 92.68 High High
Pituitary Cancer 15 89.80 High High
Infection 53 88.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, in all of the patients with short stature, the GH secretory response to three different pharmacological stimuli was evaluated, including: clonidine, growth hormone-releasing hormone (GHRH) and hypoglycemia after insulin administration.
Positive_regulation (response) of Gene_expression (evaluated) of GHRH associated with hypoglycemia, growth problems and clonidine
1) Confidence 0.50 Published 1994 Journal Horm. Res. Section Abstract Doc Link 7959619 Disease Relevance 1.00 Pain Relevance 0.10
In addition, in all of the patients with short stature, the GH secretory response to three different pharmacological stimuli was evaluated, including: clonidine, growth hormone-releasing hormone (GHRH) and hypoglycemia after insulin administration.
Positive_regulation (response) of Gene_expression (evaluated) of growth hormone-releasing hormone associated with hypoglycemia, growth problems and clonidine
2) Confidence 0.50 Published 1994 Journal Horm. Res. Section Abstract Doc Link 7959619 Disease Relevance 1.00 Pain Relevance 0.10
By analysis of the areas under the response curves it was shown that GRF 1-44 was as effective in stimulating GH release as clonidine and that a dose of 1 microgram/kg GRF 1-44 could be a good choice for use as a standard test dose in the dog.
Positive_regulation (stimulating) of Gene_expression (effective) of GRF associated with clonidine
3) Confidence 0.49 Published 1989 Journal Zentralbl Veterinarmed A Section Abstract Doc Link 2521156 Disease Relevance 0 Pain Relevance 0.18
The intravenous administration of synthetic human pancreatic growth-hormone-releasing factor (hpGRF) (10 micrograms/kg) (2 X 10(-9) mol/kg) increased (P less than 0.01) the GH concentration in both the young and old birds.
Positive_regulation (increased) of Gene_expression (synthetic) of hpGRF
4) Confidence 0.47 Published 1984 Journal Gen. Comp. Endocrinol. Section Abstract Doc Link 6439597 Disease Relevance 0 Pain Relevance 0
Bronchial endocrine neoplasms causing acromegaly due to ectopic production of growth hormone (GH)-releasing hormone (GHRH) have been reported.
Positive_regulation (causing) of Gene_expression (production) of GHRH associated with acromegaly and cancer
5) Confidence 0.46 Published 2001 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 11453963 Disease Relevance 0.52 Pain Relevance 0.07
Naloxone (20 mg IV) did not significantly alter serum prolactin levels and, minimally but not significantly, increased growth hormone levels in humans to whom it was administered.
Neg (not) Positive_regulation (increased) of Gene_expression (levels) of growth hormone associated with narcan
6) Confidence 0.42 Published 1979 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 116298 Disease Relevance 0 Pain Relevance 0.26
The intravenous administration of synthetic human pancreatic growth-hormone-releasing factor (hpGRF) (10 micrograms/kg) (2 X 10(-9) mol/kg) increased (P less than 0.01) the GH concentration in both the young and old birds.
Positive_regulation (increased) of Gene_expression (synthetic) of pancreatic growth-hormone-releasing factor
7) Confidence 0.41 Published 1984 Journal Gen. Comp. Endocrinol. Section Abstract Doc Link 6439597 Disease Relevance 0 Pain Relevance 0
In a third model, overexpression of GHS-R1a in GHRH neurons increased organ and muscle weight, while decreasing body fat in female animals [28].
Positive_regulation (increased) of Gene_expression (overexpression) of GHRH in body
8) Confidence 0.21 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.64 Pain Relevance 0
In a third model, overexpression of GHS-R1a in GHRH neurons increased organ and muscle weight, while decreasing body fat in female animals [28].
Positive_regulation (overexpression) of Gene_expression (overexpression) of GHRH in body
9) Confidence 0.21 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.63 Pain Relevance 0
Mutational disruption of constitutive GHS-R1a activity is associated with short stature in humans [27], whereas overexpression of GHS-R1a on GHRH neurons augments postweaning growth, reduces fat mass, and augments GHRH and GH gene expression in mice [28].
Positive_regulation (augments) of Gene_expression (expression) of GHRH in fat associated with growth problems
10) Confidence 0.21 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.16 Pain Relevance 0.08
Reduced pituitary action of SS is unlikely to be the sole potentiating mechanism subserving GHS action, since GHS and GHRH synergize even after immunoneutralization of SS [268].
Positive_regulation (since) of Gene_expression (synergize) of GHRH in pituitary
11) Confidence 0.21 Published 2010 Journal International Journal of Peptides Section Body Doc Link PMC2925380 Disease Relevance 0.11 Pain Relevance 0.04
Blood was sampled for levels of beta-endorphin, cortisol, human growth hormone, and prolactin.
Positive_regulation (sampled) of Gene_expression (levels) of growth hormone in Blood
12) Confidence 0.18 Published 1989 Journal Am. J. Obstet. Gynecol. Section Abstract Doc Link 2522737 Disease Relevance 0.32 Pain Relevance 0.38
At a preprogrammed time in a child's life there is an increase in the amplitude of GnRH pulses which triggers a cascade of events including increases in the amplitude of FSH and LH pulses, followed by marked increases in gonadal sex steroidal output, which in turn increases growth hormone (GH) and insulin-like growth factor-1 (IGF-1) production.
Positive_regulation (increases) of Gene_expression (production) of growth hormone in gonadal
13) Confidence 0.12 Published 1996 Journal Horm. Res. Section Abstract Doc Link 8742123 Disease Relevance 0 Pain Relevance 0.09
Many who treat children with ISS believe that by increasing adult height they are improving quality of life.50 However, there is little objective data to support this notion.51 In fact, the idea that short stature is a problem that can be addressed by GH treatment has been recently challenged in the popular press.52 Recent reviews of available instruments for evaluating quality of life in children with GHD or ISS suggest that it should be possible to do the studies that could help answer whether treatment with GH has a positive or negative effect on quality of life.53,54 The question of efficacy of GH treatment is particularly relevant because of the expense of GH therapy: perhaps as much as US$52,634 per inch.55 In spite of the difficulty of demonstrating that an increase in height also results in increased quality of life, children with ISS have been treated with GH since at least the inception of the NCGS in 1985, accounting for approximately 20% of those patients treated with GH.56 Savage57 has suggested that 1) if growth hormone therapy is restricted to a height threshold of ?
Positive_regulation (restricted) of Gene_expression (therapy) of growth hormone associated with growth hormone deficiency and growth problems
14) Confidence 0.11 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2898102 Disease Relevance 0.61 Pain Relevance 0
Resistance exercise is aimed at increasing muscle bulk, and it enhances the secretion and production of growth hormone and various growth factors [36].
Positive_regulation (enhances) of Gene_expression (production) of growth hormone in muscle
15) Confidence 0.06 Published 2006 Journal Nutr J Section Body Doc Link PMC1526446 Disease Relevance 0 Pain Relevance 0.10
Activation is a complex process characterized by increasing placental production of corticotrophin releasing hormone, activation of the fetal hypothalamic-pituitary-adrenal axis, progesterone withdrawal, and increasing estrogen and prostaglandin biosynthesis.
Positive_regulation (increasing) of Gene_expression (production) of releasing hormone in pituitary associated with withdrawal
16) Confidence 0.05 Published 2010 Journal BMC Pregnancy Childbirth Section Body Doc Link PMC2841774 Disease Relevance 0.92 Pain Relevance 0.15
Moreover, TSH adenomas may co-secrete other pituitary hormones, most frequently growth hormone and in decreasing order prolactin and gonadotropins, as well as uncombined ?
Positive_regulation (frequently) of Gene_expression (hormones) of growth hormone in pituitary associated with adenoma
17) Confidence 0.05 Published 2008 Journal Pituitary Section Body Doc Link PMC2712623 Disease Relevance 0.97 Pain Relevance 0.06
Consistent with this hypothesis, paracrine growth factors that are normally secreted by prostate stroma cells, such as epidermal growth factor (EGF), insulin-like growth factor 1 (IGF1), hepatocyte growth factor (HGF), keratinocyte growth factor (KGF) or interleukin 6 (IL6), are found to be overexpression in hormone-refractory cancer in association with a switch to autocrine production by cancer epithelial cells [16].
Positive_regulation (overexpression) of Gene_expression (overexpression) of hormone-refractory in HGF associated with cancer
18) Confidence 0.03 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2957443 Disease Relevance 0.73 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox